Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

$11.22 -0.22 (-1.92%)

High $11.49	Low $11.20	Trades 4,718	Turnover $7,499,551	Volume 664,557
30 June 2023 at 4:12pm

Market Cap (25-Aug) $5,291,697,664 (204th)	Close (30-Jun) $11.22 0 (0%)	Volume (30-Jun) 664,557	Shortsold (19-Aug) 35,298,818 (10.39%) (11th)
52w High $18.95	52w Low $8.26	P/E 156.25	EPS 0.14

Short Interest

ASIC data, 19 Aug 2026

% Shorted

10.39% 0.01

vs 10.40% prior report

Most Shorted Rank

11th

of 704 shorted ASX stocks

Peak Short

16.51%

Apr 2026

Days to Cover

19.2

at 50d avg vol

View full short position history →

	Subject
	TLX TLX Ann: Chairmans Address to AGM
	1 (current) 2 3
	TLX TLX Ann: Phase III Prostate Cancer Therapy Clinical Trial Commences
	TLX TLX Ann: Executive Leadership Appointments and Establishment of APAC
	TLX TLX Ann: Telix Appoints Mr Richard Valeix as EMEA President
	TLX TLX Ann: Manufacturing Agreement with Global Medical Solutions
	TLX TLX Ann: Activities Report and App 4C for quarter ended 31 March 2021
	TLX TLX Ann: Japanese Renal Cancer Imaging Trial Meets Study Objectives
	TLX TLX Ann: Launch of International NOBLE Registry for SPECT Imaging
	TLX TLX Ann: TGA commences priority evaluation process for Illuccix
	TLX TLX Ann: AGM Notice of Meeting and Explanatory Memorandum
	TLX TLX Ann: Agreement with GRAM for commercial manufacture of Illucix
	TLX TLX Ann: Cleansing Notice - shares issued upon exercise of options
	TLX TLX Ann: App 2A - quotation of shares issued upon exercise of options
	TLX TLX Ann: Global Agreements with ITM for Lutetium-177 Supply
	TLX TLX Ann: S&P DJI Announces March 2021 Quarterly Rebalance
	TLX TLX Ann: Cleansing Notice - issue of shares upon exercise of options
	TLX TLX Ann: App 2A - quotation of shares on exercise of options
	TLX TLX Ann: Cleansing Notice - issue of shares upon exercise of options
	TLX TLX Ann: App 2A - quotation of shares on exercise of options
	TLX TLX Ann: 2020 Annual Report
	TLX TLX Ann: Appendix 4E - Results for announcement to the market
	TLX TLX Ann: Corporate Governance Statement year ended 31 December 2020
	TLX TLX Ann: Appendix 4G - key to governance disclosures
	TLX TLX Ann: Shareholder update - year ended 31 December 2020
	TLX TLX Ann: PMDA clearance to commence Prostate Cancer Imaging Study
	TLX TLX Ann: Czech Republic Grants National Authorisation for TLX591 Kit
	TLX TLX Ann: Notification of Conference Call for FY2020 Results
	TLX TLX Ann: Collaboration with Heidelberg University Hospital
	TLX TLX Ann: Telix Pursues Direct Benelux Product Distribution
	TLX TLX Ann: Appendix 3G - issue of unlisted share options
	TLX TLX Ann: Appendix 4C and Activities Report for December 2020 Quarter
	TLX TLX Ann: First US patients dosed in Ph III ZIRCON trial
	TLX TLX Ann: TLX101 Glioblastoma Therapy - Clinical Update
	TLX TLX Article: ASX up 1.2pc; Rio Tinto’s new CEO; Afterpay hits record
	TLX TLX Ann: Cleansing Notice under section 708A Corporations Act
	TLX TLX Ann: Appendix 2A - issue of shares from exercise of options
	TLX TLX Ann: Change in substantial holding
	TLX TLX Ann: New Drug Submission filed with Health Canada for TLX591-CDx
	TLX TLX Ann: Urologic Oncology Alliance with Mauna Kea Technologies
	TLX TLX Ann: IP Agreement with U Southampton for access to TRALA data
	TLX TLX Ann: Cleansing Notice under section 708A Corporations Act
	TLX TLX Ann: Appendix 2A - issue of shares from exercise of options
	TLX TLX Ann: Appendix 2A - shares issued as consideration for acquisition
	TLX TLX Ann: Telix Completes Acquisition of TheraPharm GmbH
	TLX TLX Ann: Telix and Kanazawa University Phase I trial of TLX591-CDx
	TLX TLX Ann: Release of shares from voluntary escrow
	TLX TLX Ann: FDA New Drug Application for TLX591-CDx Proceeds to Review
	TLX TLX Ann: TGA Priority Review Granted for Prostate Cancer Imaging
	TLX TLX Ann: Overview of ProstACT Phase III Study - Investor supplement
	TLX TLX Ann: ProstACT Phase III Study Clinical Development Update

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

End of Day Prices

Date	Close	Volume	Change
25-Aug	$16.16	989,623	0.00 (0.00%)
24-Aug	$16.16	1,683,785	+0.54 (3.46%)
21-Aug	$15.62	4,582,753	-1.76 (10.13%)
20-Aug	$17.38	4,863,419	+0.54 (3.21%)
19-Aug	$16.84	974,002	+0.08 (0.48%)
18-Aug	$16.76	1,945,470	+0.31 (1.88%)
17-Aug	$16.45	1,127,014	-0.28 (1.67%)
14-Aug	$16.73	1,585,454	-0.63 (3.63%)
13-Aug	$17.36	1,420,239	+0.48 (2.84%)
12-Aug	$16.88	1,229,886	-0.07 (0.41%)
11-Aug	$16.95	1,494,281	+0.32 (1.92%)
10-Aug	$16.63	2,040,128	+0.44 (2.72%)
07-Aug	$16.19	2,630,762	+1.15 (7.65%)
06-Aug	$15.04	1,288,790	+0.32 (2.17%)
05-Aug	$14.72	1,153,983	+0.31 (2.15%)
10 up, 4 down, and 1 flat days

Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Telix Pharmaceuticals Health Care Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom